Publication Data
WO 2005/000712 A1

International Application
PCT


Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published: with international search report before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Abstract: A pharmaceutical dispensing aid (10) comprising a transparent canister (12) made of polycarbonate polymer. The canister (12) is configured to contain a formulation (14) comprising one or more active pharmaceutical ingredients, a propellant or a mixture of propellants along with any other pharmaceutically acceptable suitable excipients. The canister (12) is transparent in nature thereby providing visual dosage monitoring to the patient.
PHARMACEUTICAL DISPENSING AID

This invention in general relates to pharmaceutical dispensing aids. More particularly, this invention relates to an inhaler device for pharmaceuticals, still more particularly to a metered dose inhaler (MDI) for pharmaceuticals.

MDIs are well known in the art. A metered dose inhaler typically comprises a canister crimped with a metering valve, wherein the canister is filled with an aerosol formulation that includes a drug dissolved or dispersed in a propellant. Typically the container of the inhaler is made of jacketed glass or metal. Metallic containers are either made of tin-plated steel or aluminum. The propellants used in metered dose inhalers include chlorofluorocarbons (CFCs), hydrofluorocarbons (HFCs) or hydrofluoroalkanes (HFAs).

CFC propellants are considered to cause ozone depletion. Consequent to the Montreal Protocol and the call for banning of the CFC propellants, new ozone friendly propellants have been developed. These propellants include the HFAs. HFAs do not contain chlorine and are considered as ozone friendly.

United States Patent Number 6444028, describes a plain aluminum can for an ipratropium formulation.

United States Patent Application Number 20030066525 to Lewis David et al titled 'Pressurized metered dose inhalers (mMDI)' discloses a pressurized metered dose inhaler wherein the internal surface of the inhaler consists of stainless steel or anodized aluminum or the internal surface lined with an inert organic coating.

United States Patent Application Number 2002219743 discloses a plastic pressure bottle having a polyethylene terephthalate (PET) layer for alkaline ingredients & manufacture of laminated bottles with outer layer & polyamide inner layer.

Japanese Patent Application No. JP 200020794 discloses a container comprising a mainly PET based layer & a gas barrier layer installed in the center to the inner side of the wall. Thus a five-layered laminate for preparation of container was made from PET
as two surfaces & central layer & ethylene-vinyl alcohol copolymer (F10IBZ) as inner layer b/w the central layer & the surface.

It is known from the prior art that canisters for metered dose inhalers may be opaque. They therefore, do not provide the advantage of visible dosage monitoring of the content inside the container. This is especially needed when the canister contains a medicated formulation. The medicament may be in the form of solution or suspension. For suspensions, there exists the possibility of agglomeration. Agglomeration occurs mainly when the medicament is used infrequently or only when the patient’s condition demands in such cases, the same medicament is used for months either till it gets over or expires.

It is possible that due to the non-transparent nature of the container, the patient is unable to estimate the amount of dose remaining in the container. Therefore at the time of an emergency, the medicine may not be available or may be difficult to obtain.

It is also necessary that there be some indication by way of marking or otherwise to the patient about the amount of dosage form remaining in the canister. This can always indicate to the patient that now is the time to buy another canister and keep it in stock.

We have now found a way to enable enables the patient to visually monitor the form and content of the inhalation medicament contained in the aerosol device. The present invention therefore offers an improved canister, which imparts transparency to the canister.

It has also been observed that if the drug canister is made of polycarbonate, the drug particles of the formulation do not adhere to the inner walls of the polycarbonate container thereby imparting anti-adherent property upon the canister. This also results in giving a better uniformity of dose and content per spray.

In accordance with one embodiment, the present invention provides a pharmaceutical dispensing aid having a transparent canister, which is preferably made of a transparent polymer which is advantageously a polycarbonate polymer. The polycarbonate polymer
described herein may be bisphenol A polycarbonate polymer.

In accordance with another embodiment, the present invention provides a pharmaceutical dispensing aid having a transparent canister thus enabling the user thereof to visually monitor the content and form of the medicament contained therein.

In accordance with another embodiment, the present invention provides a pharmaceutical dispensing aid having a transparent canister with etchings or markings that indicate to the patient the level of the medicament inside the container.

In accordance with yet another embodiment, the present invention provides a pharmaceutical dispensing aid having a canister configured to contain a medicament wherein the canister is configured to prevent adhesion of the medicament to the inner wall of the canister.

In accordance with still another embodiment, the present invention provides a pharmaceutical dispensing aid for administering a medicament, the pharmaceutical dispensing aid having a canister made of polycarbonate polymer wherein the use of polycarbonate polymer prevents adhesion of the medicament to the inner surface of the canister thus enabling uniform dose content per spray.

In accordance with another embodiment, the present invention provides a pharmaceutical dispensing aid for administering a medicament, the improved pharmaceutical dispensing aid having a canister made up of polycarbonate polymer wherein the use of polycarbonate polymer imparts aesthetic elegance to the container thereby making it useful in various other fields such as cosmetology, nasal sprays, dry powder inhalers, and such other related fields.

In accordance with still another embodiment, the present invention provides a pharmaceutical dispensing aid in the form of a metered dose inhaler device.

The present invention describes an improved canister for spraying and inhalation. The canister is advantageously made of polycarbonate which makes it transparent.
In accordance with another aspect of the invention there is provided the use of polycarbonate in a canister of a metered dose inhaler to perform the dual functions of: providing sufficient transparency of the canister that a user can see the amount of formulation present within the interior of the canister; and reducing or preventing the adhesion of the formulation to the interior surface of the canister.

In accordance with another aspect of the invention there is provided the use of polycarbonate in a pharmaceutical dispenser to perform the dual functions of: providing sufficient transparency of the dispenser that a user can see the amount of formulation present within the interior of the dispenser; and reducing or preventing the adhesion of the formulation to the interior surface of the dispenser.

It will be understood from the foregoing that the preferred purpose of the polycarbonate is to provide the dual function of transparency and reducing adhesion of the formulation to the interior of the dispenser or canister. To this end, the dispenser or canister is preferably made entirely of polycarbonate. It will be appreciated, however, that the transparency function may be achieved in a dispenser or canister which is only partially made of polycarbonate (or another transparent polymer), provided that the transparency is sufficient to permit the interior contents of the dispenser or canister to be visible from the exterior. Thus, a slightly opaque dispenser or canister may be provided, even though a completely transparent canister is preferred. Furthermore, the dispenser or canister may have a generally opaque structure with one or more transparent strips which are sufficient to enable to interior contents of the dispenser or canister to be visible from the exterior.

The transparent container enables the patient to visibly monitor the content of the medicament inside the container. Therefore the patient realizes when the medicament is about to run out, and keeps another canister in stock thereby avoiding situations when the patient is in urgent need of the medication and the medicament is unavailable and difficult to obtain. Transparency of the canister also enables the patient to visualize the physical nature of the medicament. This visualization is critical when the medicament is a suspension or the medicament has not been used since a long time.
For example, before inhalation, the patient shakes the canister and realizes that the
drug particles do not disperse completely. In this way, the patient understands that the
medicament is unstable and is not fit for inhalation. Therefore transparency of the
container becomes the only means that a patient, who is untrained in this field of
expertise and the ultimate user of the medicament, realizes that this medicament is not
to be inhaled.

The canister may also bear some markings or etchings indicative of the various levels
of the content of the canister. Therefore in case of medicated formulations, especially
aerosols, the patient can then inhale the doses only in the levels that produces
pharmacologically therapeutic effects. Currently the patient has to guess how many
doses are left in the canister and has two practical options: (1) throw away the canister
that may still contain acceptable metered doses or (2) use a product when it may be
beyond the recommended number of doses and risk not receiving correct drug dose.
The former is wasteful, and the latter is potentially dangerous.

For example, if the metered dose inhaler is configured to deliver 120 puffs the actual
number of puffs filled inside the container is 20 to 30 more than the puffs mentioned on
the label. This is because the initial few and the last few puffs do not actually contain
the active ingredient in therapeutic amounts. Expulsion of the initial few doses is known
as priming of the inhaler. This is necessary so that the next dose the patient inhales
has the desired amount of drug in it. The last few puffs actually contain only the
propellant which is necessary to expel the active. The etchings or markings are
therefore indicative of the levels of the doses that are to be expelled for priming.

Usually the patient is instructed to discard the canister after inhalation of certain
number of doses. This reliance on the patient’s memory may cause serious casualties
because the patient may forget to discard the used canister, that contains only the non-
active excipients, and buy a new one. Thus the markings also indicate to the patient the
level after which the patient should not use the medicament as it only contains the
propellant and no drug.

It has also been observed that the polycarbonate canister prevents adhesion of the
active drug particles to the inner walls of the canister. This results in better uniformity of dosage and content per spray with every puff. Therefore the therapeutic performance of the canister is enhanced.

5 The canister preferably has a cylindrical body having a closed end and a round base and another end having a mouth. The cylindrical body is advantageously made up of polycarbonate polymer. The mouth is preferably crimped with a metering valve of a suitable material such as aluminum or tin. The metering valve may be entirely conventional, as described in the prior art. The capacity of the container may range from 2 ml to 50 ml. The canister may be filled with formulations such as medicated solutions or suspensions for inhalation.

The formulations include one or more active pharmaceutical ingredients. The active pharmaceutical ingredients are typically drugs useful in the treatment of respiratory diseases. The active pharmaceutical ingredients may be selected from a group comprising bronchodilators, beta-2-adrenoacceptors anticholinergics, steroids, beta-2-agonists, antiallergics and such other compounds; including their salts, derivatives, enantiomers, prodrugs and racemic mixtures thereof. The active ingredient is combined with a propellant or a mixture of propellants, preferably selected from the class of HFA propellants. The HFA propellants may be selected from 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. The formulation may optionally include other pharmaceutically acceptable excipients, such as co-solvents, surfactants and the like. Ethanol may be used as a co-solvent in the range of 1-20 wt% with respect to the formulation. The surfactants may be selected from lecithin, oleic acid, sorbitan triolcate, glycerol and the like, in the range of 0.0001-15 wt% with respect to the active.

The formulation may be provided as a solution of the active pharmaceutical substance in the propellant or as a suspension or dispersion of the active pharmaceutical substance in the propellant.

The transparent polycarbonate canister so designed is aesthetic and elegant and can be used in various other fields such as cosmetology. For cosmeceutical preparations, the canister may be fitted with a continuous valve. The capacity of the canister may
range from 10 ml to 500 ml or more as required. The canister may comprise of various
cosmetological formulations such as deodorants, hair sprays, hair mousses, air
fresheners, shaving creams etc.

5 The canister may be prepared by any method known in the art. One such suitable
illustration of a method of preparation of the said canister is as follows:

An example of a suitable manufacturing process for the polycarbonate container by
injection molding / injection blow molding will now be provided.

10 The polycarbonate needed for manufacturing the can is stored in a silo as pellets. It
will be appreciated that the polycarbonate should preferably be free of any opacifying
agent, or at least sufficiently free of opacifying agent that the visibility of the formulation
within the canister is not impaired. Before use, it is dried at 120°C. The injection-
molding machine has a variety of the sections. There is a polycarbonate reservoir.
Below is an endless screw powered by an engine, which conveys the polycarbonate to
the mold. Resistance heaters melt the plastic by raising it to a temperature of 320°C.
The mold has two sections, one fixed & one movable so that the part can be ejected.
The mold is cooled by pressurized circulating water with a temperature of 120°C.

15 Polycarbonate granules are loaded into a hopper drier kept at 80°C-90°C so as to
remove the moisture. Then these granules are injection molded/injection blow molded
(plasticized) at 220-230°C at different zones in the machine.

Reference is now made to Figure 1 which is a schematic cross sectional view of a
metered dose inhaler according to the present invention. The inhaler is generally
designated 10 and comprises a canister 12 which holds a pharmaceutical formulation
14 comprising a drug and a propellant, optionally with excipients. The canister 12 is
crimped with a metering valve 16 which comprises a crimped sealing member 18 and a
valve member 20. In use, the inhaler 10 would normally be mounted to an actuator (not
shown) to which the metering valve. The metering valve 16 and the actuator may be
entirely conventional. The canister 12 is entirely made of polycarbonate, whereby the
formulation 14 can be seen by the user through the walls of the canister 12. Markings
22 are provided on the canister 12 to give an indication of the number of doses
remaining.

Examples

The following examples of formulations are suitable for use in a metered dose inhaler according to the invention.

1. **Salbutamol Sulphate HFA4 Inhalation (200 doses).**

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Ingredients</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Salbutamol Sulphate</td>
<td>28.8 mg</td>
</tr>
<tr>
<td>2.</td>
<td>1,1,1,2-tetrafluoroethane</td>
<td>q.s.</td>
</tr>
</tbody>
</table>

2. **Ipratropium HFA Inhalation (200 doses)**

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Ingredients</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Ipratropium</td>
<td>24 mg</td>
</tr>
<tr>
<td>2.</td>
<td>1,1,1,2-tetrafluoroethane</td>
<td>q.s.</td>
</tr>
</tbody>
</table>

3. **Budesonide HFA Inhalation (200 doses)**

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Ingredients</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Budesonide</td>
<td>48 mg</td>
</tr>
<tr>
<td>2.</td>
<td>Ethanol</td>
<td>2.73 gms</td>
</tr>
<tr>
<td>3.</td>
<td>Lecithin</td>
<td>0.24 mg</td>
</tr>
<tr>
<td>4.</td>
<td>1,1,1,2,3,3,3-heptfluoropropane</td>
<td>q.s.</td>
</tr>
</tbody>
</table>

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be made by those skilled in the art, and such modifications and variations are considered to fall
within the scope of the invention.
Claims

1. A metered dose inhaler comprising a canister and a metering valve attached to the canister, wherein the canister is sufficiently transparent that a formulation disposed within the canister is visible from the exterior of the canister.

2. A metered dose inhaler according to claim 1, wherein the canister is entirely transparent.

3. A metered dose inhaler according to claim 1 or 2, wherein the canister is at least partially made of polycarbonate.

4. A metered dose inhaler according to claim 1 or 2, wherein the canister is entirely made of polycarbonate.

5. A metered dose inhaler comprising a canister and a metering valve attached to the canister, wherein the canister is polycarbonate.

6. A metered dose inhaler according to any preceding claim, wherein the canister is provided with markings indicative of the number of doses of formulation remaining in the canister.

7. A metered dose inhaler according to any preceding claim, further comprising a formulation containing an active pharmaceutical substance selected from the group of bronchodilators, long acting bronchodilators, beta-2-adrenoceptors, anticholinergics, steroids, beta-2-agonists and antiallergics.

8. A metered dose inhaler according to claim 7, wherein the active pharmaceutical substance is salbutamol, ipratropium or budesonide.

9. A metered dose inhaler according to claim 7 or 8 wherein the formulation further comprises a propellant.
10. A metered dose inhaler according to any preceding claim, wherein the canister is polycarbonate and does not have any coating on the interior surface thereof.

11. A metered dose inhaler according to any preceding claim, further comprising an actuator for actuating the metering valve.

12. A metered dose inhaler according to claim 11, wherein the actuator is configured such that, in use, it does not prevent the user from seeing the level of formulation in the canister.

13. A method of making a metered dose inhaler, comprising forming a polycarbonate canister by injection molding or injection blow molding, placing a pharmaceutical formulation in the canister, then securing a metering valve to the canister.

14. The use of polycarbonate in a canister of a metered dose inhaler to perform the dual functions of: providing sufficient transparency of the canister that a user can see the amount of formulation present within the interior of the canister; and reducing or preventing the adhesion of the formulation to the interior surface of the canister.

15. The use of polycarbonate in a pharmaceutical dispenser to perform the dual functions of: providing sufficient transparency of the dispenser that a user can see the amount of formulation present within the interior of the dispenser; and reducing or preventing the adhesion of the formulation to the interior surface of the dispenser.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 B65D83/14 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 B65D A61M A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>GB 2 195 544 A (UNIVERSAL PRECISION MOULDERS L) 13 April 1988 (1988-04-13)</td>
<td>1,2,7-9, 11,12</td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>3-5,10, 13-15</td>
</tr>
<tr>
<td></td>
<td>page 1, paragraph 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 1, paragraph 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 1, paragraph 7 - paragraph 10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 2, paragraph 19 - paragraph 21; figures 1-5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>column 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>column 3, line 9 - line 16</td>
<td></td>
</tr>
<tr>
<td></td>
<td>column 5, line 47 - line 50; claims 1,2</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. [X]

Patent family members are listed in annex. [X]

* Special categories of cited documents:

**A** document defining the general state of the art which is not considered to be of particular relevance

**E** earlier document but published on or after the international filing date

**L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but later than the priority date claimed

**T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**X** document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**Y** document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

**Z** document member of the same patent family

Date of the actual completion of the international search: 18 October 2004

Date of mailing of the international search report: 27/10/2004

Nama and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Mans-Kamerbeek, M

Form PCT/ISA/210 (second sheet) (January 2004)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 96/32345 A (ASHURST IAN C; LI LI (US); HERMAN CRAIG S (US); RIEBE MICHAEL T (US)); 17 October 1996 (1996-10-17) page 1, line 10 - page 2, line 14 page 5, line 29 - line 30</td>
<td></td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>GB 2195544  A</td>
<td>13-04-1988</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2418613 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0216235 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004506495 T</td>
</tr>
<tr>
<td>US 3746196  A</td>
<td>17-07-1973</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 258813 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 718851 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 5481296 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 102023 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9604979 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2218179 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1186473 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9703261 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69631476 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EA 889 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 9700372 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2214536 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 9800641 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000513237 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 974738 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 306281 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OA 10625 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 322781 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 139197 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TR 9701170 T1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9632345 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6511652 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6511653 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6149892 A</td>
</tr>
</tbody>
</table>